NYSEHealth CareHealth Care ServicesS&P SmallCap 600
$31.29
-0.55 (-1.73%)
Close of Nov 06, 2026 · end-of-day data
MD 8-K filings in 2024
Every material Form 8-K Pediatrix Medical filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Pediatrix disclosed that Dr. Curtis B. Pickert, its Executive Vice President and Chief Physician Executive and a former Chief Operating Officer, will transition out of his role effective January 31, 2025. The company notified him on November 29, 2024, and the departure is treated as a termination without Cause under his employment agreement, with benefits payable after he signs a general release. The filing does not describe a successor or any financial impact.
Dr. Curtis B. Pickert's transition is effective January 31, 2025.
The company notified Dr. Pickert of the transition on November 29, 2024.
The departure is a termination without Cause under his Second Amended and Restated Employment Agreement dated April 26, 2023.
Benefits are payable only after Dr. Pickert signs a general release of claims in favor of the company.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Pediatrix Medical filing is on SEC EDGAR ↗. 8-K briefs of other companies →